Cerebellar stroke in a low cardiovascular risk patient associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma

KEY CLINICAL MESSAGE: Sorafenib is the standard treatment of hepatocellular carcinoma (HCC). However, fibrolamellar HCC was not included in sorafenib trials. The case is a 26-year-old man with fibrolamellar HCC, who had a cerebrovascular accident (CVA) while being treated with sorafenib. This illust...

Descripción completa

Detalles Bibliográficos
Autores principales: Vandewynckel, Yves-Paul, Geerts, Anja, Verhelst, Xavier, Van Vlierberghe, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184762/
https://www.ncbi.nlm.nih.gov/pubmed/25356226
http://dx.doi.org/10.1002/ccr3.34
Descripción
Sumario:KEY CLINICAL MESSAGE: Sorafenib is the standard treatment of hepatocellular carcinoma (HCC). However, fibrolamellar HCC was not included in sorafenib trials. The case is a 26-year-old man with fibrolamellar HCC, who had a cerebrovascular accident (CVA) while being treated with sorafenib. This illustrates a probable relationship between use of sorafenib and CVA in low cardiovascular risk patients.

Ejemplares similares